Does Dr. MEGHA AGARWAL have financial conflicts of interest?

Dr. MEGHA AGARWAL (M.D.) has received a total of $4,754 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $4,754 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MEGHA AGARWAL?

According to CMS Open Payments data, Dr. MEGHA AGARWAL received funding from KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC ($3,802), ASTRAZENECA PHARMACEUTICALS ($276), and ABBOTT LABORATORIES ($140).

Does Dr. MEGHA AGARWAL receive research grants or speaking fees?

Dr. MEGHA AGARWAL has received $4,754 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MEGHA AGARWAL

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Cardiovascular Disease

Practice Location: SIMI VALLEY, CA 93065

NPI Number: 1508011958

LIFETIME INDUSTRY VALUE

$4,754

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. AGARWAL is a verified Internal Medicine, Cardiovascular Disease practitioner based in SIMI VALLEY, CA.

Between 2021 and 2024, Dr. AGARWAL had an overall industry promotional and research financial footprint of $4,754 as recorded in the federal CMS Open Payments database.

$4,754 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. AGARWAL's primary funding source is KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC, which accounts for $3,802 (representing 80% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC

Rank 1

$3,802

80%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$276

5.8%

ABBOTT LABORATORIES

Rank 3

$140

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.